Cargando…

Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.

A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (8...

Descripción completa

Detalles Bibliográficos
Autores principales: Terashima, M., Hayashi, K., Fukushima, M., Ide, H., Iizuka, T., Kakegawa, T., Ando, N., Tanaka, O., Shinoda, M., Isono, K., Ishida, K., Ikeuchi, S., Endo, M., Takiyama, W., Yanagawa, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074605/
https://www.ncbi.nlm.nih.gov/pubmed/8679462
_version_ 1782138002442551296
author Terashima, M.
Hayashi, K.
Fukushima, M.
Ide, H.
Iizuka, T.
Kakegawa, T.
Ando, N.
Tanaka, O.
Shinoda, M.
Isono, K.
Ishida, K.
Ikeuchi, S.
Endo, M.
Takiyama, W.
Yanagawa, T.
author_facet Terashima, M.
Hayashi, K.
Fukushima, M.
Ide, H.
Iizuka, T.
Kakegawa, T.
Ando, N.
Tanaka, O.
Shinoda, M.
Isono, K.
Ishida, K.
Ikeuchi, S.
Endo, M.
Takiyama, W.
Yanagawa, T.
author_sort Terashima, M.
collection PubMed
description A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (80%) were evaluable for drug response. Cells (3 x 10(3) ml-1 well-1) were cultured for 14 days and exposed to drugs on days 3-8. Growing cells were confirmed as cancer cells by immunohistochemical staining. IC90 values against several anti-cancer drugs were determined and population distributions of IC90 for each drug served as the basis for judging sensitivity. The 10th percentiles of IC90 (microgram ml-1) for CDDP, 5-FU, DOX, CPM, MTX, VP16, IFOS, VDS, BLM and CDDP + 5-FU were 0.3, 0.16, 0.005, 0.9, 0.006, 0.09, 0.8, 0.006, 0.04 and 0.15 + 0.09 respectively. The population distribution of IC90 against each drug showed a specific pattern that was very similar among histopathological gradings and stages of the disease. This system appeared to be a clinically applicable drug sensitivity test for human oesophageal cancer. IMAGES:
format Text
id pubmed-2074605
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20746052009-09-10 Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. Terashima, M. Hayashi, K. Fukushima, M. Ide, H. Iizuka, T. Kakegawa, T. Ando, N. Tanaka, O. Shinoda, M. Isono, K. Ishida, K. Ikeuchi, S. Endo, M. Takiyama, W. Yanagawa, T. Br J Cancer Research Article A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (80%) were evaluable for drug response. Cells (3 x 10(3) ml-1 well-1) were cultured for 14 days and exposed to drugs on days 3-8. Growing cells were confirmed as cancer cells by immunohistochemical staining. IC90 values against several anti-cancer drugs were determined and population distributions of IC90 for each drug served as the basis for judging sensitivity. The 10th percentiles of IC90 (microgram ml-1) for CDDP, 5-FU, DOX, CPM, MTX, VP16, IFOS, VDS, BLM and CDDP + 5-FU were 0.3, 0.16, 0.005, 0.9, 0.006, 0.09, 0.8, 0.006, 0.04 and 0.15 + 0.09 respectively. The population distribution of IC90 against each drug showed a specific pattern that was very similar among histopathological gradings and stages of the disease. This system appeared to be a clinically applicable drug sensitivity test for human oesophageal cancer. IMAGES: Nature Publishing Group 1996-07 /pmc/articles/PMC2074605/ /pubmed/8679462 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Terashima, M.
Hayashi, K.
Fukushima, M.
Ide, H.
Iizuka, T.
Kakegawa, T.
Ando, N.
Tanaka, O.
Shinoda, M.
Isono, K.
Ishida, K.
Ikeuchi, S.
Endo, M.
Takiyama, W.
Yanagawa, T.
Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
title Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
title_full Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
title_fullStr Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
title_full_unstemmed Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
title_short Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
title_sort drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074605/
https://www.ncbi.nlm.nih.gov/pubmed/8679462
work_keys_str_mv AT terashimam drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT hayashik drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT fukushimam drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT ideh drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT iizukat drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT kakegawat drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT andon drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT tanakao drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT shinodam drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT isonok drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT ishidak drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT ikeuchis drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT endom drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT takiyamaw drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem
AT yanagawat drugsensitivitytestingforclinicalsamplesfromoesophagealcancerusingadhesivetumourcellculturesystem